Trials
1 active
2 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Administered via intravesical instillation directly into the urinary bladder. Participants in the experimental group receive a total of 6 instillations on Days 1, 3, 5, 8, 15, and 22 over approximately 1 month prior to TURBT. During each treatment, participants are asked to retain the solution in the bladder for up to 2 hours.”In the company’s words, NCT07804056 on ClinicalTrials.gov
- Main trialPhase 3
- “The goal of this clinical trial is to learn if the drug Alpha1H works to treat low-to-intermediate risk non-muscle-invasive bladder cancer in adults. It will also learn about the safety of drug Alpha1H. The main questions it aims to answer are: * Does giving drug Alpha1H before surgery lower the risk of cancer returning or worsening compared to standard care alone? * Is drug Alpha1H safe and well-tolerated by participants? Researchers will compare participants receiving drug Alpha1H before standard surgery to participants receiving standard care alone to see if drug Alpha1H lowers the risk…”In the company’s words, NCT07804056 on ClinicalTrials.gov
Other drugs for Urinary Bladder Neoplasms
- Cretostimogene GrenadenorepvecCG Oncology, Inc. · Phase 3
- Nogapendekin alfa inbakiceptImmunityBio · Phase 2/3
- Disitamab vedotinPfizer · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- CetrelimabJohnson & Johnson (Janssen) · Phase 3
- TAR-200Johnson & Johnson (Janssen) · Phase 3
Coming up1
- Jul 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jul 2029 | A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer | |
| Phase 1/2Ended | not given | A Randomized Placebo controlled Phase I/II Study Evaluating the Safety and Efficacy of Alpha1H in adult patients with non-muscle invasive bladder cancer awaiting transurethral surgery |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026